Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$28.9 million.

  • Adma Biologics' Net Cash Flow fell 1780.29% to -$28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.3 million, marking a year-over-year decrease of 301.77%. This contributed to the annual value of $51.8 million for FY2024, which is 247.27% up from last year.
  • Adma Biologics' Net Cash Flow amounted to -$28.9 million in Q3 2025, which was down 254.88% from $18.7 million recorded in Q2 2025.
  • Adma Biologics' 5-year Net Cash Flow high stood at $51.6 million for Q4 2022, and its period low was -$31.5 million during Q1 2025.
  • Its 3-year average for Net Cash Flow is -$2.3 million, with a median of -$6.0 million in 2024.
  • In the last 5 years, Adma Biologics' Net Cash Flow soared by 741.44% in 2024 and then plummeted by 1,780.29% in 2025.
  • Adma Biologics' Net Cash Flow (Quarterly) stood at $16.7 million in 2021, then soared by 209.48% to $51.6 million in 2022, then crashed by 144.18% to -$22.8 million in 2023, then skyrocketed by 172.09% to $16.4 million in 2024, then tumbled by 1,780.29% to -$28.9 million in 2025.
  • Its Net Cash Flow stands at -$28.9 million for Q3 2025, versus $18.7 million for Q2 2025 and -$31.5 million for Q1 2025.